GILD Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 27.55% compared to Gilead Sciences, Inc.'s net margin of 20.83%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Johnson & Johnson's return on equity of 34.46%.

Gilead Sciences, Inc. has a consensus price target of $151.12, signalling downside risk potential of -2.49%. On the other hand Johnson & Johnson has an analysts' consensus of $231.25 which suggests that it could fall by -5.01%. Given that Johnson & Johnson has more downside risk than Gilead Sciences, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Johnson & Johnson.

Gilead Sciences, Inc. has a beta of 0.360, which suggesting that the stock is 63.985% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.04%. Johnson & Johnson offers a yield of 2.11% to investors and pays a quarterly dividend of $1.30 per share. Gilead Sciences, Inc. pays 46.61% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $7.9B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Gilead Sciences, Inc.'s net income of $2.2B is lower than Johnson & Johnson's net income of $5.1B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 22.86x while Johnson & Johnson's PE ratio is 22.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.61x versus 6.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 27.55% compared to Gilead Sciences, Inc.'s net margin of 34.4%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Eli Lilly & Co.'s return on equity of 104.39%.

Gilead Sciences, Inc. has a consensus price target of $151.12, signalling downside risk potential of -2.49%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 15.54%. Given that Eli Lilly & Co. has higher upside potential than Gilead Sciences, Inc., analysts believe Eli Lilly & Co. is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.360, which suggesting that the stock is 63.985% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.04%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.73 per share. Gilead Sciences, Inc. pays 46.61% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $7.9B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Gilead Sciences, Inc.'s net income of $2.2B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 22.86x while Eli Lilly & Co.'s PE ratio is 46.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.61x versus 14.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 27.55% compared to Gilead Sciences, Inc.'s net margin of 18.06%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Merck & Co., Inc.'s return on equity of 39.63%.

Gilead Sciences, Inc. has a consensus price target of $151.12, signalling downside risk potential of -2.49%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.86%. Given that Merck & Co., Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Merck & Co., Inc. is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.360, which suggesting that the stock is 63.985% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.04%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Gilead Sciences, Inc. pays 46.61% of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $7.9B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Gilead Sciences, Inc.'s net income of $2.2B is lower than Merck & Co., Inc.'s net income of $3B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 22.86x while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.61x versus 4.68x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 27.55% compared to Gilead Sciences, Inc.'s net margin of 21.74%. Gilead Sciences, Inc.'s return on equity of 41.72% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Gilead Sciences, Inc. has a consensus price target of $151.12, signalling downside risk potential of -2.49%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 8.08%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.360, which suggesting that the stock is 63.985% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.04%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Gilead Sciences, Inc. pays 46.61% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences, Inc. quarterly revenues are $7.9B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Gilead Sciences, Inc.'s net income of $2.2B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 22.86x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 6.61x versus 6.08x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.